This white paper, curated and reviewed by HITLAB, is an independent, evidence-based report of the CERN Device , which is an emerging therapeutic innovation in women’s health. With HITLAB’s expertise in digital health innovation, usability research, medical devices value proposition, and clinical validation, this paper assesses the device’s safety, mechanism of action, and potential clinical value in the management of recurrent bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) based on the evidence studies conducted.

The paper talks about the challenges that the CERN Device addresses within the broader landscape of vaginitis care, by highlighting persistent gaps related to antimicrobial resistance, biofilm-driven recurrence, microbiome disruption, and patient quality of life. It further demonstrates how the CERN Device proposes a non-drug, microbiome-preserving, home-use therapeutic model that aligns with modern, patient-centered care pathways. It validates clinical promise, may complement or, in select cases, reduce reliance on traditional antibiotics and antifungals.

Importantly, HITLAB identifies the device’s user-friendly care at home potential to support safer long-term management, improve adherence, and telehealth integration. This contributes to more sustainable healthcare delivery, positioning the CERN Device as a forward-looking solution in an area of substantial unmet clinical need.

CERN Device highlights a dual value proposition: improving women’s quality of life while reducing long- term healthcare burden associated with recurrent infections, repeated prescriptions, and downstream complications. As women’s health moves toward precision, prevention, and personalization, the CERN Device stands as a compelling example of how thoughtful, evidence-based innovation can reshape the future of gynecologic care.